The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The impact of metformin on progression-free survival of patients with advanced pancreatic well-differentiated neuroendocrine tumor receiving everolimus plus somatostatin analog treatment.
Sara Pusceddu
No relevant relationships to disclose
Roberto Buzzoni
No relevant relationships to disclose
Luca Giacomelli
Consultant or Advisory Role - Novartis
Vincenzo Mazzaferro
No relevant relationships to disclose
Laura Concas
No relevant relationships to disclose
Massimo Milione
No relevant relationships to disclose
Barbara Formisano
No relevant relationships to disclose
Elisa D'Autilia
No relevant relationships to disclose
Fabrizio Festinese
No relevant relationships to disclose
Filippo G. De Braud
No relevant relationships to disclose